GlobeImmune Inc. (NASDAQ: GBIM) share price has surged over 33% out of the gate in this mornings early trading session hitting $2.17 before settling back at $1.77. There’s no sign of any news at the moment, however trading volume is way above average with over 2,000,000 shares being traded at the time of this post, investor speculation could be at play here. GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture. In 2009, the Company entered into a worldwide strategic collaboration and option agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates intended to treat cancer.